A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP
Conditions : Diffuse Large B-cell Lymphoma Interventions : Drug: Polatuzumab vedotin, Glofitamab Sponsors : Yonsei University Not yet recruiting
Read the full article2d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
STAT+: Fresh turmoil roils American Diabetes Association following controversy at conference
STAT·1h ago
Brain Implants Are Physically Rewiring Damaged Spines
yesilscience.com·1h ago
Predicting biotech clinical trials & a new Alzheimer’s drug controversy
STAT·2h ago
STAT+: GOP blocks effort to end Medicare test of AI prior authorization
STAT·4h ago
Blood-based gene expression tests show potential for early pancreatic cancer detection
news-medical.net·4h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.